Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 4, Issue 1, 2013, Pages 53-61

  Ji, Linong ^a   Onishi, Yukiko ^b   Ahn, Chul Woo ^c   Agarwal, Pankaj ^d   Chou, Chien Wen ^e   Haber, Harry ^f   Guerrettaz, Kelly ^g   Boardman, Marilyn K ^h  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c Yonsei University College of Medicine   (South Korea)

^d Hormone Care and Research Center   (India)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f PharmaNet/i3   (United States)

^g Pharmanet i3   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Asian; Exenatide; Type 2 diabetes

Indexed keywords

AMYLASE; ANTIEMETIC AGENT; C REACTIVE PROTEIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; ADULT; ANKLE FRACTURE; AORTA ANEURYSM; ARTICLE; BODY MASS; BRAIN INFARCTION; BRONCHOPNEUMONIA; CALCITONIN BLOOD LEVEL; CEREBRAL PALSY; CHINA; CHRONIC SINUSITIS; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DECREASED APPETITE; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTENDED RELEASE FORMULATION; FALLING; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAEMOPHILUS INFECTION; HUMAN; HYPERCHLORHYDRIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INDIA; INFECTION; INFESTATION; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSULIN SENSITIVITY; JAPAN; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOULDER IMPINGEMENT SYNDROME; SIDE EFFECT; SMALL INTESTINE HEMORRHAGE; SOUTH KOREA; STEADY STATE; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TAIWAN; TENDON RUPTURE; TRANSIENT GLOBAL AMNESIA; VAGINA BLEEDING; VITREOUS HEMORRHAGE; VOMITING; WAIST HIP RATIO; WEIGHT CHANGE;

EID: 84873152483     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00238.x     Document Type: Article

References (37)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Hu FB. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-1257.
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
4. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002; 3: 141-146.
5. Nakagami T, Qiao Q, Carstensen B, et al. Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003; 46: 1063-1070.
6. Chan WB, Tong PC, Chow CC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients. Diabet Med 2004; 21: 349-353.
7. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831-835.
8. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
10. International Diabetes Federation. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2005. Available at http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (accessed 6 July 2011).
11. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
12. Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
15. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
16. Bydureon (exenatide) [abbreviated prescribing information]. Eli Lilly and Company Limited, Basingstoke, 2011. Available at http://www.bydureonlaunch.co.uk/templates/lilly/bydureon/ downloads/prescribing-information.pdf (accessed 3 August 2011).
17. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
18. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
19. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
20. Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest 2011; 2: 210-217.
21. Kadowaki T, Namba M, Yamamura A, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
22. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
23. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
24. Zinman B, Hoogwerf BJ, Duran GarciaS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
25. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
26. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493.
27. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28: 705-714.
28. Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009; 56: 951-962.
29. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
30. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
31. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
32. Diamant M, Van GaalL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
33. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34: 77-98.
34. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
35. Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417.
36. Anderson J, Shive M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
37. Fineman MS, Mace MF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554.